1005 ET - Regenerative stem cell-based therapies are poised for a breakthrough as the potential for approvals looks set to thrive in a more favorable regulatory environment, says Maxim Group's Jason McCarthy in a research note. The analyst says such therapies came onto the scene in the mid-2010s and contracted shortly afterwards, but can now step back into the limelight. McCarthy notes that two companies that have benefited from recent changes are Mesoblast and Capricor Therapeutics, with valuations of both rising significantly this year. He adds that RFK Jr., Trump's pick to run the Department of Health and Human Services, seems enthusiastic about stem cell research despite criticizing vaccines and fluoride. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
December 12, 2024 10:05 ET (15:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。